MRNS - Marinus Pharmaceuticals GAAP EPS of -$0.67 beats by $0.13 revenue of $10.38M beats by $5.47M

2023-05-11 07:07:12 ET

• Marinus Pharmaceuticals press release ( NASDAQ: MRNS ): Q1 GAAP EPS of -$0.67 beats by $0.13 .
• Revenue of $10.38M (-26.8% Y/Y) beats by $5.47M .
• For the fiscal year 2023, the Company maintains its prior guidance with expected ZTALMY U.S. net product revenues of between $15 million and $17 million, BARDA revenues in the range of $8 million to $11 million and total GAAP operating expenses, inclusive of SG&A and R&D, in the range of $165 to $175 million, of which the company expects stock-based compensation of approximately $16 million.
• Expect that cash, cash equivalents, and short-term investments of $199.2 million as of March 31, 2023, will be sufficient to fund the Company’s operating expenses, capital expenditure requirements and maintain the minimum cash balance of $15 million required under the Company’s debt facility into the second half of 2024.

For further details see: